The Philips CPAP Recall: What Happened, What Philips Knew, and What It Means for You
The full story behind the largest CPAP recall in history — 15+ million devices, toxic foam, a company that knew for years, and the $1.55 billion in settlements that followed.
The Recall at a Glance
- June 14, 2021: Philips Respironics announces voluntary recall
- Devices recalled: 15–16 million worldwide (3–4 million in U.S.)
- Problem: PE-PUR sound abatement foam degrading, releasing toxic particles and gases
- FDA classification: Class I recall (most serious)
- Adverse events: 116,000+ reports to FDA; 561 deaths
- MDL: MDL 3014 — Western District of Pennsylvania (Judge Joy Flowers Conti)
- Economic Loss settlement: $445 million (September 2023)
- Personal Injury settlement: $1.1 billion (April 2024)
The Problem: Foam That Poisons Your Airway
Philips Respironics built its CPAP, BiPAP, and ventilator devices with polyester-based polyurethane (PE-PUR) foam as a sound abatement material — designed to make the machines quieter. This foam sits in the air pathway of the device, meaning air flowing to the user passes directly through or around it.
Over time — accelerated by heat, humidity, and ozone cleaning — this foam degrades. As it degrades:
- Visible black particles break off the foam and enter the tubing and mask
- Volatile organic compounds (VOCs) off-gas from the foam into the air pathway
- Chemical compounds including formaldehyde, diethylene glycol, and phenol are released
- Testing identified compounds that are classified as possible and probable human carcinogens
Users were breathing these particles and gases directly into their lungs — every night, while sleeping, for months and years at a time.
The Timeline
Devices Manufactured and Sold
Philips sells DreamStation, SystemOne, and other CPAP/BiPAP models to millions of patients globally. Devices are prescribed through sleep clinics, hospitals, and the VA. Patients use them as directed — nightly, for years.
Philips Internally Aware of Foam Issues
According to litigation documents and regulatory filings, Philips was receiving internal reports about PE-PUR foam degradation as early as 2015. Field safety notices and medical device corrections were contemplated internally. No public warning was issued.
Philips Issues Field Safety Notice in Europe
Philips issues a field safety notice in certain European markets about the foam degradation issue — months before publicly notifying American patients.
U.S. Voluntary Recall Announced
Philips Respironics announces a voluntary recall of affected devices in the United States. The company estimates 3–4 million devices were sold in the U.S. Globally, 15+ million devices are affected. Patients are advised to stop using their devices — or continue if no alternative exists, after consulting their physicians.
FDA Issues Class I Recall Classification
The FDA classifies the Philips CPAP recall as Class I — the most serious category, indicating that use of the recalled device could cause serious adverse health consequences or death. The FDA begins receiving adverse event reports at an extraordinary rate.
116,000+ Adverse Event Reports Filed
The FDA receives more than 116,000 medical device adverse event reports related to the Philips recall — including 561 reports of death. Patients report cancers, respiratory damage, and other serious conditions they attribute to recalled device use.
MDL 3014 Established
The U.S. Judicial Panel on Multidistrict Litigation consolidates the rapidly growing number of Philips CPAP lawsuits into MDL 3014 — In Re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation — in the Western District of Pennsylvania.
$445 Million Economic Loss Settlement
Philips reaches a $445 million settlement to resolve economic loss claims — compensation for device owners whose recalled CPAP/BiPAP devices became worthless. This is Track 1 of the dual settlement structure.
$1.1 Billion Personal Injury Settlement
Philips announces a $1.1 billion settlement to resolve personal injury claims from users who developed health conditions — including cancer and respiratory disease — from exposure to degraded foam particles and gases. This is Track 2 of the dual settlement structure.
FDA Consent Decree & Claims Processing
The FDA enters a consent decree with Philips — banning the company from manufacturing certain CPAP and BiPAP devices at U.S. facilities until compliance with quality standards is verified. Settlement claims are being processed through the MDL. New claimants continue to be enrolled by attorneys.
What Philips Knew — The Core Allegation
The central allegation in the Philips CPAP litigation is not just that the devices were defective — it's that Philips knew about the foam degradation problem years before the public recall and failed to warn patients, physicians, or the FDA in a timely manner.
Plaintiffs allege that Philips:
- Had internal reports of foam degradation as early as 2015
- Received complaints about black particles from users before the recall
- Conducted testing that showed toxic compounds in foam degradation products
- Issued a safety notice in Europe months before telling American patients
- Continued selling devices during this period without adequate warnings
These allegations form the basis of both the economic loss claims (selling a defective product) and the personal injury claims (failure to warn of known health risks).
Used a Recalled Philips Device? Time to Act.
The settlements are in place. Claims are being processed. But deadlines vary by state — and the claims process is complex. Find out where you stand in 2 minutes.
Check My Settlement Eligibility →